Application of the variability budget approach to the Dissolution test

Q3 Pharmacology, Toxicology and Pharmaceutics
D. Leontiev, Vitalii Asmolov, N. Volovyk, Oleksandr Gryzodub
{"title":"Application of the variability budget approach to the Dissolution test","authors":"D. Leontiev, Vitalii Asmolov, N. Volovyk, Oleksandr Gryzodub","doi":"10.15587/2519-4852.2024.299217","DOIUrl":null,"url":null,"abstract":"The aim. This study aimed to evaluate the completeness of our knowledge about the sources of variation in the Dissolution test with 100 % release by compiling a variability budget. \nMaterials and methods. The study was performed on 500 mg metformin tablets, using pharmacopoeial quality reagents, State Pharmacopoeia of Ukraine (SPhU) Metformin HCl reference standard, Pharmatest DT70 Dissolution apparatus, Perkin Elmer Lambda 35 spectrophotometer, Mettler Toledo XP 204 analytical balance, and ISO class A volumetric glassware. The SPhU metrological approach was employed. \nResults and discussion. The variability budget was compiled based on the comparison of uncertainty estimates obtained from the requirements for maximum permissible variation in normal analytical practice (UNAP, bottom-up estimation) and experimental data (Uexp). This involved characterizing Metformin content in tablets using the Uniformity of Dosage Units (UDU) test as an independent method. The 100 % release of Metformin in the Dissolution test (infinity point) was proved by increasing the dissolution time. Having optimized Dissolution and UDU analytical procedures for variability budget compiling, we achieved insignificance of Uexp compared to the target uncertainty (Utg) for the Dissolution test in compliance testing. The differences in UDU and Dissolution mean results did not exceed UNAP for the release time of 45 and 60 min, i.e. uncertainty budget was proven. Uexp for the Dissolution test indicated the presence of an unknown statistically significant source of random variation, which, however, was less than Utg; therefore, the procedure is suitable for compliance testing. \nConclusion. Experimental results confirmed the completeness of our knowledge about sources of variation (absence of bias) for the Dissolution test with 100 % release. An essential condition for compiling the budget was the optimization of uncertainty of analytical procedures. For UDU, all significant sources of variation were within the expected range. Yet, there is a need for additional research to identify and manage an unknown source of practically significant random variation for the Dissolution test","PeriodicalId":21674,"journal":{"name":"ScienceRise: Pharmaceutical Science","volume":"2018 36","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ScienceRise: Pharmaceutical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15587/2519-4852.2024.299217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

The aim. This study aimed to evaluate the completeness of our knowledge about the sources of variation in the Dissolution test with 100 % release by compiling a variability budget. Materials and methods. The study was performed on 500 mg metformin tablets, using pharmacopoeial quality reagents, State Pharmacopoeia of Ukraine (SPhU) Metformin HCl reference standard, Pharmatest DT70 Dissolution apparatus, Perkin Elmer Lambda 35 spectrophotometer, Mettler Toledo XP 204 analytical balance, and ISO class A volumetric glassware. The SPhU metrological approach was employed. Results and discussion. The variability budget was compiled based on the comparison of uncertainty estimates obtained from the requirements for maximum permissible variation in normal analytical practice (UNAP, bottom-up estimation) and experimental data (Uexp). This involved characterizing Metformin content in tablets using the Uniformity of Dosage Units (UDU) test as an independent method. The 100 % release of Metformin in the Dissolution test (infinity point) was proved by increasing the dissolution time. Having optimized Dissolution and UDU analytical procedures for variability budget compiling, we achieved insignificance of Uexp compared to the target uncertainty (Utg) for the Dissolution test in compliance testing. The differences in UDU and Dissolution mean results did not exceed UNAP for the release time of 45 and 60 min, i.e. uncertainty budget was proven. Uexp for the Dissolution test indicated the presence of an unknown statistically significant source of random variation, which, however, was less than Utg; therefore, the procedure is suitable for compliance testing. Conclusion. Experimental results confirmed the completeness of our knowledge about sources of variation (absence of bias) for the Dissolution test with 100 % release. An essential condition for compiling the budget was the optimization of uncertainty of analytical procedures. For UDU, all significant sources of variation were within the expected range. Yet, there is a need for additional research to identify and manage an unknown source of practically significant random variation for the Dissolution test
将变异性预算方法应用于溶解试验
目的本研究旨在通过编制变异性预算,评估我们对 100% 释放溶出度测试变异性来源的了解是否完整。材料和方法研究使用药典质量试剂、乌克兰国家药典(SPhU)盐酸二甲双胍参考标准、Pharmatest DT70 溶解仪、珀金埃尔默 Lambda 35 分光光度计、梅特勒-托利多 XP 204 分析天平和 ISO A 级容量玻璃器皿,对 500 毫克二甲双胍片剂进行了测试。采用了 SPhU 计量方法。结果与讨论。变异性预算是根据正常分析实践中最大允许变异要求(UNAP,自下而上的估计)和实验数据(Uexp)得出的不确定性估计值进行比较后编制的。这包括使用剂量单位均匀性(UDU)测试作为独立方法来确定片剂中二甲双胍含量的特征。通过延长溶出时间,证明二甲双胍在溶出试验(无穷点)中的释放率为 100%。通过优化溶出度和剂量单位(UDU)分析程序以编制变异性预算,我们在合规性测试中使溶出度测试的不确定性(Uexp)与目标不确定性(Utg)相差不大。在 45 分钟和 60 分钟的释放时间内,UDU 和溶解度平均结果的差异没有超过 UNAP,也就是说,不确定性预算得到了证实。溶解度测试的 Uexp 表明存在未知的统计意义上的随机变化源,但小于 Utg;因此,该程序适用于符合性测试。结论实验结果证实,我们对 100%释放的溶解试验的变异源(无偏差)的了解是完整的。编制预算的一个基本条件是优化分析程序的不确定性。就 UDU 而言,所有重要的变异源都在预期范围内。然而,还需要进行更多的研究,以确定和管理溶解度测试中实际存在的重大随机变异的未知来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ScienceRise: Pharmaceutical Science
ScienceRise: Pharmaceutical Science Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.70
自引率
0.00%
发文量
39
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信